Sanofi completes the $1.7bn acquisition of Inhibrx
With the completed acquisition, Sanofi will gain access to SAR447537, Inhibrx’s human recombinant protein in development for AATD.
With the completed acquisition, Sanofi will gain access to SAR447537, Inhibrx’s human recombinant protein in development for AATD.
What's Your Reaction?
